CP-100356 monohydrochloride

C₃₁H₃₆N₄O₆ · HCl

597.10

MFCD00911858

329823745

NA.77

CP-100356 is a specific inhibitor of MDR1 (P-Gp), the protypical ABC transporter. The compound has low uM to nM potency for inhibiting several MDR-1 substrates (calcein-AM, digoxin) in transfected MDCKII cells. CP-100356 also inhibits prazosin transport in human breast cancer resistance protein (BCRP)-transfected MDCKII cells, suggesting that it acts as a dual inhibitor. CP-100356 does not inhibit multidrug resistance-associated protein 2 (MPR2 IC₅₀ >15 mM).

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound was developed by Pfizer for ADME/Tox research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.

To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Sold for research purposes under agreement from Pfizer Inc.
Pfizer is a registered trademark of Pfizer, Inc.

100

>98% (HPLC)

powder

Pfizer^®

white to off-white

DMSO: >5 mg/mL

Pfizer

2-8℃

Cl.COc1ccc(CCNc2nc(N3CCc4cc(OC)c(OC)cc4C3)c5cc(OC)c(OC)cc5n2)cc1OC

1S/C31H36N4O6.ClH/c1-36-24-8-7-19(13-25(24)37-2)9-11-32-31-33-23-17-29(41-6)28(40-5)16-22(23)30(34-31)35-12-10-20-14-26(38-3)27(39-4)15-21(20)18-35;/h7-8,13-17H,9-12,18H2,1-6H3,(H,32,33,34);1H

WWCHXVYTCMPAMV-UHFFFAOYSA-N

5, 25 mg in glass bottle

13 - Non Combustible Solids

WGK 3